Oncolytic potency and reduced virus tumorspecificity in oncolytic virotherapy. A mathematical modelling approach

Simple item page
dc.contributor.authorMahasa, Khaphetsi Josephen_ZA
dc.contributor.authorEladdadi, Aminaen_ZA
dc.contributor.authorDe Pillis, Lisetteen_ZA
dc.contributor.authorOuifki, Rachiden_ZA
dc.date.accessioned2018-11-14T06:29:19Z
dc.date.available2018-11-14T06:29:19Z
dc.date.issued2017
dc.descriptionCITATION: Mahasa, K. J., et al. 2017. Oncolytic potency and reduced virus tumorspecificity in oncolytic virotherapy. a mathematical modelling approach. PLoS ONE 12(9):e0184347, doi:10.1371/journal.pone.0184347.
dc.descriptionThe original publication is available at https://journals.plos.org/plosone
dc.description.abstractIn the present paper, we address by means of mathematical modeling the following main question: How can oncolytic virus infection of some normal cells in the vicinity of tumor cells enhance oncolytic virotherapy? We formulate a mathematical model describing the interactions between the oncolytic virus, the tumor cells, the normal cells, and the antitumoral and antiviral immune responses. The model consists of a system of delay differential equations with one (discrete) delay. We derive the model’s basic reproductive number within tumor and normal cell populations and use their ratio as a metric for virus tumor-specificity. Numerical simulations are performed for different values of the basic reproduction numbers and their ratios to investigate potential trade-offs between tumor reduction and normal cells losses. A fundamental feature unravelled by the model simulations is its great sensitivity to parameters that account for most variation in the early or late stages of oncolytic virotherapy. From a clinical point of view, our findings indicate that designing an oncolytic virus that is not 100% tumor-specific can increase virus particles, which in turn, can further infect tumor cells. Moreover, our findings indicate that when infected tissues can be regenerated, oncolytic viral infection of normal cells could improve cancer treatment.en_ZA
dc.description.urihttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184347
dc.description.versionPublisher's version
dc.format.extent25 pages
dc.identifier.citationMahasa, K. J., et al. 2017. Oncolytic potency and reduced virus tumorspecificity in oncolytic virotherapy. a mathematical modelling approach. PLoS ONE 12(9):e0184347, doi:10.1371/journal.pone.0184347
dc.identifier.issn1932-6203 (online)
dc.identifier.otherdoi:10.1371/journal.pone.0184347
dc.identifier.urihttp://hdl.handle.net/10019.1/104683
dc.language.isoen_ZAen_ZA
dc.publisherPublic Library of Science
dc.rights.holderAuthors retain copyright
dc.subjectOncogenic viruses -- Mathematical modelsen_ZA
dc.subjectTumors -- Immunological aspectsen_ZA
dc.subjectVirus-induced immunosuppressionen_ZA
dc.subjectCancer invasiveness -- Mathematical modelsen_ZA
dc.titleOncolytic potency and reduced virus tumorspecificity in oncolytic virotherapy. A mathematical modelling approachen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mahasa_oncolytic_2017.pdf
Size:
5.37 MB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles ((SACEMA) South African Centre for Epidemiological Modelling and Analysis )